26Jan 2023
Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy

The study aimed to explore serological responses to SARS-CoV-2 vaccination in patients treated with immunotherapy (IO) and describe the level of immune stimulation using parameters such as blood cytokines, autoantibody levels and immune-related adverse events (irAEs) post-vaccination. For the first time, the study reported that anti-SARS-CoV-2 vaccination elicited the generation of five autoantibodies. The significantly increased autoantibodies were IgM autoantibodies against beta-2 glycoprotein, myeloperoxidase, nucleosome, SPLUNC2 and IgG autoantibody against Myosin Heavy Chain 6. Overall, comprehensive analysis of a small cohort showed that co-administration of the SARS-CoV-2 vaccine and IO is not associated with increased irAEs. Nevertheless, the detection of autoantibodies post-anti-SARS-CoV-2 vaccination warrants further investigation.

  • #family health

Like

Save

Share